Screener
Ironwood Pharmaceuticals IRWD Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:09 PM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-020489
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Net cash provided by operating activities | 127,044 | 103,549 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (34) | (142) |
| Net cash used in investing activities | (34) | (142) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 216 | 11,013 |
| Taxes paid related to net share settlement of share-based awards | — | (737) |
| Repayment of 2024 Convertible Notes | — | (200,000) |
Item 16. Form 10-K Summary
FAQ
- What is Ironwood Pharmaceuticals's investing cash flow?
- Ironwood Pharmaceuticals (IRWD) reported investing cash flow of $0 in Q4 2025.
- What is the long-term trend for Ironwood Pharmaceuticals's investing cash flow?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's investing cash flow has grown at a -42.8% compound annual growth rate (CAGR), from -$326.75K to -$35K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Ironwood Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude